GlobeNewswire Inc | Sep 21, 2020 08:25AM EDT

September 21, 2020

Late-breaking ESMO presentation shows Libtayo (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of 50%

-- In the overall trial population, Libtayo reduced risk of death by 32% compared to chemotherapy -- In a prespecified analysis of patients with confirmed PD-L1 expression of 50%, Libtayo reduced risk of death by 43%

PARIS and TARRYTOWN, N.Y. September 21, 2020 - Positive pivotal trial data for the investigational use of PD-1 inhibitor Libtayo (cemiplimab) in first-line locally advanced or metastatic non-small cell lung cancer (NSCLC) were shared in a presentation at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

The trial compared Libtayo monotherapy to platinum-doublet chemotherapy in patients whose tumor cells expressed PD-L1, including those whose cancers had confirmed PD-L1 expression of 50%.These results form the basis of regulatory submissions, including in the U.S. and European Union.

In new analyses presented at ESMO, Libtayo reduced the risk of death by 43% in patients whose cancer had confirmed PD-L1 expression of 50% or greater. This is notable given that nearly three-quarters of patients crossed over from chemotherapy following disease progression and 12% of patients had pretreated and stable brain metastases, said Ahmet Sezer, M.D., Associate Professor in the Department of Medical Oncology at Bakent University in Adana, Turkey and a trial investigator. These results support Libtayo as a potential new option for anti-PD-1 monotherapy in first-line advanced non-small cell lung cancer.

The late-breaking ESMO presentation expands on topline results shared in April. In the overall trial population (n=710), the median follow-up was 13 months for both Libtayo (n=356; range: <1-32 months) and chemotherapy (n=354; range: <1-32 months). Among these patients, Libtayo demonstrated the following results compared to chemotherapy:

-- 32% reduced risk of death (hazard ratio [HR]=0.68; 95% confidence interval [CI]: 0.53-0.87; p=0.0022). -- 22-month median overall survival (OS; 95% CI: 18 months to not yet evaluable) compared to 14 months (95% CI: 12-19 months). -- 41% reduced risk of disease progression (HR=0.59; 95% CI: 0.49-0.72; p<0.0001). The median progression-free survival (PFS) was 6.2 months (95% CI: 4.5-8.3 months) compared to 5.6 months (95% CI: 4.5-6.1 months). -- 37% objective response rate (ORR; 95% CI: 32-42%; 3% complete response [CR] and 33% partial response [PR] rate) compared to 21% ORR (95% CI: 17-25%; 1% CR and 20% PR rate).

A prespecified analysis of data from patients whose cancers had confirmed PD-L1 expression 50% (n=563) was also conducted. In this group, the median follow-up was 11 months for both Libtayo (n=283; range: <1-32 months) and chemotherapy (n=280; range: <1-30 months), and Libtayo demonstrated the following results compared to chemotherapy:

-- 43% reduced risk of death (HR=0.57; 95% CI: 0.42-0.77; p=0.0002). -- Median OS was not yet reached (95% CI: 18 months to not yet evaluable) compared to 14 months (95% CI: 11-18 months). -- 46% reduced risk of disease progression (HR=0.54; 95% CI: 0.43-0.68; p<0.0001). The median PFS was 8 months (95% CI: 6-9 months) compared to 6 months (95% CI: 5-6 months). -- 39% ORR (95% CI: 34-45%; 2% CR and 37% PR rate) compared to 20% ORR (95% CI: 16-26%; 1% CR and 19% PR rate).

The trial also found a direct correlation between tumor response and PD-L1 expression level in Libtayo-treated patients. The ORR was highest (46%; range: 36-56%) in tumors with 90% PD-L1 expression, with target tumors shrinking by more than 40% after 6 months of treatment on average (per last observation carried forward method). This correlation with PD-L1 expression level was not observed with chemotherapy.

In the overall trial population, the median duration of exposure to Libtayo was 27 weeks (range: <1-115 weeks) and 18 weeks for chemotherapy (range: <1-87 weeks). Overall adverse events (AEs) occurred in 88% of Libtayo patients and 94% of chemotherapy patients. Grade 3 or higher AEs occurred in 37% of Libtayo patients and 49% of chemotherapy patients. Immune-mediated AEs were reported in 17% of Libtayo patients and included hypothyroidism (6%), hyperthyroidism (4%), pneumonitis (2%), hepatitis (2%), skin adverse reaction (2%), arthritis, increased blood thyroid stimulating hormone, thyroiditis, colitis, nephritis and peripheral neuropathy (each 1%). Treatment discontinuation due to an AE occurred in 6% of Libtayo patients and 4% of chemotherapy patients. No new Libtayo safety signals were observed.

Libtayo is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. The use of Libtayo to treat advanced NSCLC is investigational and has not been fully evaluated by any regulatory authority.

About the Phase 3 trialThe open-label, randomized, multi-center Phase 3 trial investigated the first-line treatment of Libtayo monotherapy compared to platinum-doublet chemotherapy in squamous or non-squamous advanced NSCLC that tested positive for PD-L1 in 50% of tumor cells but not ALK, EGFR or ROS1. PD-L1 expression was confirmed using the PD-L1 IHC 22C3 pharmDx kit. The trial included 712 patients with either locally advanced NSCLC (Stage IIIB/C), who were not candidates for surgical resection or definitive chemoradiation or had progressed after treatment with definitive chemoradiation, or previously untreated metastatic NSCLC (Stage IV).

Patients were randomized 1:1 to receive either Libtayo 350 mg administered intravenously every three weeks for up to 108 weeks or an investigator-selected, standard-of-care, platinum-based, doublet chemotherapy regimen for 4 to 6 cycles (with or without histology relevant maintenance pemetrexed chemotherapy). The co-primary endpoints are OS and PFS, and secondary endpoints include overall response rate, duration of response and quality of life.

The trial was designed to reflect current and emerging treatment paradigms. Inclusion criteria allowed patients with NSCLC who had: controlled hepatitis B, hepatitis C or HIV; pre-treated and stable brain metastases; and/or locally advanced disease that had progressed after definitive chemoradiation. Patients whose disease progressed in the trial were able to change their therapy: those in the chemotherapy arm were allowed to crossover into the Libtayo arm, while those in the Libtayo arm were allowed to combine Libtayo treatment with 4 to 6 cycles of chemotherapy.

A prespecified interim analysis was performed after 50% of OS events. Due to a highly significant improvement in OS at the interim analysis, the trial was modified to allow all patients to receive Libtayo based on an Independent Data Monitoring Committee recommendation.

About non-small cell lung cancerLung cancer is the leading cause of cancer death worldwide, with more than 2.2 million new cases expected globally in 2020. Approximately 85% of all lung cancers are NSCLC, and an estimated 25% to 30% of these cases are expected to test positive for PD-L1 in 50% of tumor cells. While immunotherapies have transformed advanced NSCLC treatment in recent years, there remains an unmet need to optimize the identification and treatment of patients with high PD-L1 expression and offer additional treatment options.

About LibtayoLibtayo is a fully-human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T-cells. By binding to PD-1, Libtayo has been shown to block cancer cells from using the PD-1 pathway to suppress T-cell activation.

Libtayo is the first immunotherapy approved in the U.S., EU, and other countries for adults with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. In the U.S., the generic name for Libtayo in its approved indication is cemiplimab-rwlc, with rwlc as the suffix designated in accordance with Nonproprietary Naming of Biological Products Guidance for Industry issued by the U.S. Food and Drug Administration. Outside of the U.S., the generic name for Libtayo in its approved indication is cemiplimab.

The extensive clinical program for Libtayo is focused on difficult-to-treat cancers. In skin cancer, this includes trials in adjuvant and neoadjuvant CSCC in addition to a pivotal trial in advanced BCC. Libtayo is also being investigated in pivotal trials in NSCLC and cervical cancer, as well as in trials combining Libtayo with either conventional or novel therapeutic approaches for both solid tumors and blood cancers. These potential uses are investigational, and their safety and efficacy have not been evaluated by any regulatory authority.

About Regeneron Pharmaceuticals, Inc.

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietaryVelociSuitetechnologies, such asVelocImmune which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.



About Sanofi

Sanofi is dedicated to supporting people through their health challenges. Weare a global biopharmaceutical company focused on human health. We preventillness with vaccines, provide innovative treatments to fight pain and easesuffering. We stand by the few who suffer from rare diseases and the millionswith long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transformingscientific innovation into healthcare solutions around the globe.

Sanofi, Empowering Life

Sanofi Media Relations ContactSally BainTel.: +1 (781) 264-1091 Sanofi Investor Relations Contacts Parissally.bain@sanofi.com Eva Schaefer-Jansen Arnaud Delepine Yvonne Naughton



Sanofi Investor Relations Contacts North America Felix Lauscher Fara Berkowitz Suzanne Greco



IR main line: Tel.: +33 (0)1 53 77 45 45 ir@sanofi.com



Regeneron Investor Relations Contact Vesna TosicRegeneron Media Relations Contact Tel.: +1 914 847 5443Daren Kwok vesna.tosic@regeneron.com Tel.: +1 914 847 1328daren.kwok@regeneron.com

Sanofi Forward-Looking StatementsThis press release contains forward-looking statements as defined in thePrivate Securities Litigation Reform Act of 1995, as amended. Forward-lookingstatements are statements that are not historical facts. These statementsinclude projections and estimates regarding the marketing and other potentialof the product, or regarding potential future revenues from the product.Forward-looking statements are generally identified by the words ?expects?,?anticipates?, ?believes?, ?intends?, ?estimates?, ?plans? and similarexpressions. Although Sanofi?s management believes that the expectationsreflected in such forward-looking statements are reasonable, investors arecautioned that forward-looking information and statements are subject tovarious risks and uncertainties, many of which are difficult to predict andgenerally beyond the control of Sanofi, that could cause actual results anddevelopments to differ materially from those expressed in, or implied orprojected by, the forward-looking information and statements. These risks anduncertainties include among other things, unexpected regulatory actions ordelays, or government regulation generally, that could affect the availabilityor commercial potential of the product, the fact that product may not becommercially successful, the uncertainties inherent in research anddevelopment, including future clinical data and analysis of existing clinicaldata relating to the product, including post marketing, unexpected safety,quality or manufacturing issues, competition in general, risks associated withintellectual property and any related future litigation and the ultimateoutcome of such litigation, and volatile economic and market conditions, andthe impact that COVID-19 will have on us, our customers, suppliers, vendors,and other business partners, and the financial condition of any one of them, aswell as on our employees and on the global economy as a whole. Any materialeffect of COVID-19 on any of the foregoing could also adversely impact us. Thissituation is changing rapidly and additional impacts may arise of which we arenot currently aware and may exacerbate other previously identified risks. Therisks and uncertainties also include the uncertainties discussed or identifiedin the public filings with the SEC and the AMF made by Sanofi, including thoselisted under ?Risk Factors? and ?Cautionary Statement Regarding Forward-LookingStatements? in Sanofi?s annual report on Form 20-F for the year ended December31, 2019. Other than as required by applicable law, Sanofi does not undertakeany obligation to update or revise any forward-looking information orstatements.

Regeneron Forward-Looking Statements and Use of Digital MediaThis press release includes forward-looking statements that involve risks anduncertainties relating to future events and the future performance of RegeneronPharmaceuticals, Inc. (?Regeneron? or the ?Company?), and actual events orresults may differ materially from these forward-looking statements. Words suchas ?anticipate,? ?expect,? ?intend,? ?plan,? ?believe,? ?seek,? ?estimate,?variations of such words, and similar expressions are intended to identify suchforward-looking statements, although not all forward-looking statements containthese identifying words. These statements concern, and these risks anduncertainties include, among others, the impact of SARS-CoV-2 (the virus thathas caused the COVID-19 pandemic) on Regeneron?s business and its employees,collaborators, and suppliers and other third parties on which Regeneron relies,Regeneron?s and its collaborators? ability to continue to conduct research andclinical programs, Regeneron?s ability to manage its supply chain, net productsales of products marketed by Regeneron and/or its collaborators (collectively,?Regeneron?s Products?), and the global economy; the nature, timing, andpossible success and therapeutic applications of Regeneron?s Products andRegeneron?s product candidates and research and clinical programs now underwayor planned, including without limitation Libtayo^ (cemiplimab); thelikelihood, timing, and scope of possible regulatory approval and commerciallaunch of Regeneron?s product candidates and new indications for Regeneron?sProducts, such as Libtayo for the treatment of non-small cell lung cancer,basal cell carcinoma, adjuvant and neoadjuvant cutaneous squamous cellcarcinoma, and cervical cancer (as well as in trials combining Libtayo witheither conventional or novel therapeutic approaches for both solid tumors andblood cancers, as applicable); uncertainty of market acceptance and commercialsuccess of Regeneron?s Products and product candidates and the impact ofstudies (whether conducted by Regeneron or others and whether mandated orvoluntary) on the commercial success of Regeneron's Products and productcandidates; safety issues resulting from the administration of Regeneron?sProducts (such as Libtayo) and product candidates in patients, includingserious complications or side effects in connection with the use of Regeneron?sProducts and product candidates in clinical trials; determinations byregulatory and administrative governmental authorities which may delay orrestrict Regeneron?s ability to continue to develop or commercializeRegeneron?s Products and product candidates; ongoing regulatory obligations andoversight impacting Regeneron?s Products, research and clinical programs, andbusiness, including those relating to patient privacy; the availability andextent of reimbursement of Regeneron?s Products from third-party payers,including private payer healthcare and insurance programs, health maintenanceorganizations, pharmacy benefit management companies, and government programssuch as Medicare and Medicaid; coverage and reimbursement determinations bysuch payers and new policies and procedures adopted by such payers; competingdrugs and product candidates that may be superior to, or more cost effectivethan, Regeneron?s Products and product candidates; the extent to which theresults from the research and development programs conducted by Regeneron and/or its collaborators may be replicated in other studies and/or lead toadvancement of product candidates to clinical trials, therapeutic applications,or regulatory approval; the ability of Regeneron to manufacture and managesupply chains for multiple products and product candidates; the ability ofRegeneron?s collaborators, suppliers, or other third parties (as applicable) toperform manufacturing, filling, finishing, packaging, labeling, distribution,and other steps related to Regeneron?s Products and product candidates;unanticipated expenses; the costs of developing, producing, and sellingproducts; the ability of Regeneron to meet any of its financial projections orguidance and changes to the assumptions underlying those projections orguidance; the potential for any license or collaboration agreement, includingRegeneron's agreements with Sanofi, Bayer, and Teva Pharmaceutical IndustriesLtd. (or their respective affiliated companies, as applicable), to be cancelledor terminated without any further product success; and risks associated withintellectual property of other parties and pending or future litigationrelating thereto (including without limitation the patent litigation and otherrelated proceedings relating to EYLEA^ (aflibercept) Injection, Dupixent^(dupilumab), and Praluent^ (alirocumab)), other litigation and otherproceedings and government investigations relating to the Company and/or itsoperations, the ultimate outcome of any such proceedings and investigations,and the impact any of the foregoing may have on Regeneron's business,prospects, operating results, and financial condition. A more completedescription of these and other material risks can be found in Regeneron?sfilings with the U.S. Securities and Exchange Commission, including its Form10-K for the year ended December 31, 2019 and its Form 10-Q for the quarterlyperiod ended June 30, 2020. Any forward-looking statements are made based onmanagement?s current beliefs and judgment, and the reader is cautioned not torely on any forward-looking statements made by Regeneron. Regeneron does notundertake any obligation to update publicly any forward-looking statement,including without limitation any financial projection or guidance, whether as aresult of new information, future events, or otherwise.

Regeneron uses its media and investor relations website and social mediaoutlets to publish important information about the Company, includinginformation that may be deemed material to investors. Financial and otherinformation about Regeneron is routinely posted and is accessible onRegeneron's media and investor relations website ( http://newsroom.regeneron.com) and its Twitter feed ( http://twitter.com/regeneron).

Attachment

-- Press Release